THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in any doubt about any of the contents of this circular or as to what action to take in relation to this circular, you should consult appropriate independent advisers to obtain independent professional advice.

If you have sold or transferred all your shares in Far East Pharmaceutical Technology Company Limited, you should at once hand this circular to the purchaser or the transferee or to the bank, licensed securities dealer or other agent through whom the sale or transfer was effected for transmission to the purchaser or the transferee.

FAR EAST PHARMACEUTICAL TECHNOLOGY COMPANY LIMITED

遠東生物制藥科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 399)

PROPOSED CHANGE OF COMPANY NAME

A notice dated 3rd February 2009 convening the extraordinary general meeting of the Company (the "**EGM**") to be held at Conference Room 2, Hong Kong General Chamber of Commerce, 22/F., United Centre, 95 Queensway, Hong Kong on Thursday, 26th February 2009 at 3:30 p.m. is set out on pages 5 to 6 of this circular. Whether or not you are able to attend the EGM, you are strongly urged to complete and sign the enclosed form of proxy, in accordance with the instructions printed thereon, and to lodge them with the branch share registrar of the Company in Hong Kong, Tricor Tengis Limited at 26th Floor, Tesbury Centre, 28 Queen's Road East, Wanchai, Hong Kong, as soon as possible but in any event not later than 48 hours before the time appointed for the holding of the EGM or any adjourned meeting (as the case may be). Completion and return of the form of proxy will not preclude you from attending and voting in person at the EGM or any adjourned meeting should you so wish.

3rd February 2009

CONTENTS

Pages

DEFINITIONS

In this circular, unless the context otherwise requires, the following expressions have the following meanings:

"Board"	the board of Directors
"Change of Company Name"	the change of the English name of the Company from "Far East Pharmaceutical Technology Company Limited" to "United Gene High-Tech Group Limited" and the Chinese name of the Company from "遠東生物制藥科技有限公司" to "聯合基因科技集團有限公司"
"Company"	Far East Pharmaceutical Technology Company Limited, an exempted company incorporated in the Cayman Islands with limited liability, the Shares of which are listed on the main board of the Stock Exchange
"Director(s)"	director(s) including independent non-executive director(s) of the Company
"EGM"	the extraordinary general meeting of the Company to be convened in relation to the proposed Change of Company Name
"Group"	the Company, its subsidiaries and jointly controlled entities
"HK$"	Hong Kong dollars, the lawful currency of Hong Kong
"Hong Kong"	the Hong Kong Special Administrative Region of the People's Republic of China
"Listing Rules"	the Rules Governing the Listing of Securities on the Stock Exchange
"Share(s)"	ordinary share(s) of HK$0.01 each in the share capital of the Company
"Shareholder(s)"	holder(s) of the Share(s)
"Stock Exchange"	The Stock Exchange of Hong Kong Limited

FAR EAST PHARMACEUTICAL TECHNOLOGY COMPANY LIMITED

遠東生物制藥科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 399)

Executive Directors:
Mr. Tai Kai Hing
Mr. Shen Xiao-dong
Mr. Jiang Jian

Independent non-executive Directors:
Mr. Chiu Koon Shou, Victor
Mr. Chung Wai Man
Dr. Leung Wai Cheung

Registered Office:
Cricket Square, Hutchins Drive
P.O. Box 2681, Grand Cayman KY 1-1111
Cayman Islands

Head Office and principal place of business in Hong Kong
Unit G, 12/F, Seabright Plaza
9–23 Shell Street, North Point
Hong Kong

3rd February 2009

To the Shareholders

Dear Sir or Madam,

PROPOSED CHANGE OF COMPANY NAME

INTRODUCTION

As announced by the Company on 19th January 2009, the Board resolved that the English name of the Company be changed from "Far East Pharmaceutical Technology Company Limited" to "United Gene High-Tech Group Limited" and the Chinese name of the Company be changed from "遠東生物制藥科技有限公司" to "聯合基因科技集團有限公司".

The purpose of this circular is to provide you with information to enable you to make a decision on whether to vote for or against the special resolution with respect to the proposed Change of Company Name at the EGM.

CONDITIONS

The proposed Change of Company Name is subject to (i) the passing of a special resolution by the Shareholders at the forthcoming EGM; and (ii) the approval by the Registrar of Companies in the Cayman Islands.

REASONS FOR THE CHANGE OF COMPANY NAME

The Board believes that the Change of Company Name would provide a better identification of the intended business of the Company and its subsidiaries in the future, to reflect the changing of the Company's controlling shareholder, and to enhance business activities for the distribution of gene testing services.

EFFECT ON CHANGE OF COMPANY NAME

Subject to the satisfaction of the conditions set out above, the Change of Company Name will take effect from the date of entry of the new name of the Company on the register of companies maintained by the Registrar of Companies in the Cayman Islands. The Company will then carry out all necessary filing procedures in respect of the Change of Company Name with the Registrar of Companies in Hong Kong.

The Change of Company Name will not affect any of the rights of any Shareholders. All existing share certificates of the Company in issue bearing the existing English and Chinese names of the Company will, after the Change of Company Name became effective, continue to be evidence of legal title to the Shares and will be valid for trading, settlement and registration purposes. However, Shareholders, if so elect, may exchange the existing share certificates for new share certificates bearing the new names of the Company at the branch share registrar of the Company in Hong Kong, Tricor Tengis Limited at 26th Floor, Tesbury Centre, 28 Queen's Road East, Wanchai, Hong Kong, free of charge for one month from the effective date of the Change of Company Name. New share certificates of the Company will be issued under the new names of the Company after the Change of Company Name becomes effective.

Further announcement will be made by the Company in relation to the effective date of the Change of Company Name and change in stock short name of Shares in both English and Chinese.

EGM

The EGM will be convened and held to consider and, if thought fit, approve the proposed Change of Company Name.

The notice of the EGM is set out on pages 5 to 6 of this circular. A form of proxy for use at the EGM is enclosed. Whether or not you are able to attend the EGM, please complete and return the enclosed form of proxy in accordance with the instructions printed thereon to the branch share registrar of the Company in Hong Kong, Tricor Tengis Limited at 26th Floor, Tesbury Centre, 28 Queen's Road East, Wanchai, Hong Kong, as soon as possible and in any event not less than 48 hours before the time appointed for the holding of the EGM or any adjournment thereof. Completion and return of the form of proxy will not preclude you from attending and voting in person at the EGM or any adjourned meeting should you wish.

Pursuant to the amendments to the Listing Rules which became effective on 1st January 2009, any vote of shareholders at a general meeting must be taken by poll and accordingly, the special resolution in relation to the proposed Change of Company Name will be put to vote by way of poll at the EGM. Further announcement on the results of the poll vote will be made by the Company after the EGM.

RESPONSIBILITY STATEMENT

This circular includes particulars given in compliance with the Listing Rules for the purpose of giving information with regard to the Group. The Directors collectively and individually accept full responsibility for the accuracy of the information contained in this circular and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, there are no other facts not contained in this circular, the omission of which would make any statement herein misleading.

RECOMMENDATION

The Board considers that the proposed Change of Company Name is in the interests of the Company and the Shareholders. Accordingly, the Board recommends the Shareholders to vote in favour of the special resolution with respect to the proposed Change of Company Name at the EGM.

Yours faithfully,
By order of the Board
Tai Kai Hing
Executive Director

FAR EAST PHARMACEUTICAL TECHNOLOGY COMPANY LIMITED

遠東生物制藥科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 399)

NOTICE IS HEREBY GIVEN that an extraordinary general meeting (the "**EGM**") of Far East Pharmaceutical Technology Company Limited (the "**Company**") will be held at Conference Room 2, Hong Kong General Chamber of Commerce, 22/F., United Centre, 95 Queensway, Hong Kong on Thursday, 26th February 2009 at 3:30 p.m. for the purpose of considering and, if thought fit, passing the following resolution of the Company:

SPECIAL RESOLUTION

"**THAT**, subject to and conditional upon the approval of the Registrar of Companies in the Cayman Islands, the English name of the Company be changed from "Far East Pharmaceutical Technology Company Limited" to "United Gene High-Tech Group Limited" and the Chinese name of the Company be changed from "遠東生物制藥科技有限公司" to "聯合基因科技集團有限公司", and the directors of the Company be and are hereby authorized generally to do all such acts and things and sign or execute all such documents or make such arrangements as they may, in their absolute discretion, consider necessary or expedient to effect and implement the change of English and Chinese names of the Company."

By order of the board of
Far East Pharmaceutical Technology Company Limited
Tai Kai Hing
Executive Director

Hong Kong, 3rd February 2009

Principal Place of Business in Hong Kong:
Unit G, 12/F, Seabright Plaza,
9-23 Shell Street, North Point,
Hong Kong

Notes:

1. Any member entitled to attend and vote at the EGM is entitled to appoint another person as his proxy to attend and vote on his behalf. A member who is the holder of two or more shares may appoint more than one proxy to attend on the same occasion. A proxy need not be a member of the Company. If more than one proxy is so appointed, the appointment shall specify the number and class of shares in respect of which each such proxy so appointed.

2. Where there are joint registered holders of any shares, any one of such persons may vote at the EGM (or at any adjournment thereof), either personally or by proxy, in respect of such shares as if he is solely entitled thereto; but if more than one of such joint holders are present at the above meeting personally or by proxy, that one of the said persons so present whose name stands first on the register of members of the Company in respect of such shares shall alone be entitled to vote in respect thereof.

3. In order to be valid, the form of proxy, together with any power of attorney or other authority (if any) under which it is signed, or a notarially certified copy thereof, must be lodged with the Company's branch share registrar in Hong Kong, Tricor Tengis Limited at 26th Floor, Tesbury Centre, 28 Queen's Road East, Wanchai, Hong Kong, not less than 48 hours before the time appointed for holding the EGM or any adjournment thereof.